Trial Profile
A Real-World Population-Based Observational Study: Comparative Safety of Abatacept in Rheumatoid Arthritis with co-morbid chronic obstructive pulmonary disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 18 Sep 2019
Price :
$35
*
At a glance
- Drugs Abatacept (Primary) ; Adalimumab; Anakinra; Certolizumab pegol; Etanercept; Golimumab; Infliximab; Rituximab; Tocilizumab; Tofacitinib
- Indications Rheumatoid arthritis
- Focus Adverse reactions
- 03 Sep 2019 Results assessing safety of biologic versus conventional synthetic DMARDs in rheumatoid arthritis with chronic obstructive pulmonary disease (COPD), published in the Rheumatology.
- 15 Jun 2019 Results (n=7,424 new users of biologic DMARDs matched to 7,424 new users of non-biologic DMARDs) presented at the 20th Annual Congress of the European League Against Rheumatism
- 14 Jul 2018 New trial record